RGNX is focused on developing, commercializing and licensing recombinant adeno-associated virus gene therapy with a proprietary delivery platform to treat rare diseases. RGNX is commercializing gene therapy products administered directly into the body, or in vivo, based on a NAV Technology Platform. Its NAV Technology Platform is currently being applied in the development of 23 product candidates for a variety of diseases, Regenxbio said, with exclusive rights to over 100 patents and patent applications worldwide.
May 17, 2016
RegMed’s closing bell: caught in the dilemma of discounted value
May 16, 2016
RegMed’s closing bell: upside actions seem impulsive but, it’s always good to start the week on a positive note
May 11, 2016
RegMed’s closing bell: another lower Wednesday
May 9, 2016
RegMed’s closing bell: it was time for an upside
May 2, 2016
RegMed’s closing bell: Dow and NASDAQ are up as sector sees divergence and disengagement
April 29, 2016
RegMed’s closing bell: more profit taking and weakness ends a tough month
April 25, 2016
RegMed’s close: sector slips positive to neutral to negative on low volumes
April 20, 2016
RegMed’s close: the sector wearied as it encountered some key resistance
April 18, 2016
RegMed’s close: there are no crystal balls here…
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.